检索结果 - Chen, Bingliang

Identification of a Gene Signature to Aid Treatment Decisions by Integrated Analysis of Mutated Genes Between Primary and Metastatic Prostate Cancer 由 Li, Qinyu, Xiao, Xueyan, Chen, Bingliang, Song, Guoda, Zeng, Kai, Miao, Jianping

获取全文 获取全文 获取全文

A novel antibody targeting TIM-3 resulting in receptor internalization for cancer immunotherapy 由 Kuang, Zhihui, Li, Li, Zhang, Pan, Chen, Bingliang, Wu, Min, Ni, Haiqing, Yi, Shuai, Zou, Jia, Liu, Junjian

获取全文 获取全文 获取全文

Preclinical characterization of Sintilimab, a fully human anti-PD-1 therapeutic monoclonal antibody for cancer 由 Zhang, Shuang, Zhang, Min, Wu, Weiwei, Yuan, Zhijun, Tsun, Andy, Wu, Min, Chen, Bingliang, Li, Jia, Miao, Xiaoniu, Miao, Xiaoliang, Liu, Xiaolin, Yu, Dechao, Liu, Junjian

获取全文 获取全文 获取全文

Lower Urinary Tract Symptoms and Sexual Dysfunction in Male: A Systematic Review and Meta-Analysis 由 Song, Guoda, Wang, Min, Chen, Bingliang, Long, Gongwei, Li, Hao, Li, Rui, Liu, Zhuo, Wei, Chao, Wang, Tao, Wang, Shaogang, Liu, Jihong, Zhang, Yucong, Liu, Xiaming

获取全文 获取全文 获取全文

Durable blockade of PD-1 signaling links preclinical efficacy of sintilimab to its clinical benefit 由 Wang, Jie, Fei, Keke, Jing, Hua, Wu, Zhihai, Wu, Weiwei, Zhou, Shuaixiang, Ni, Haiqing, Chen, Bingliang, Xiong, Yan, Liu, Yanpeng, Peng, Bo, Yu, Dechao, Jiang, Haiping, Liu, Junjian

获取全文 获取全文 获取全文

Dose escalation PET imaging for safety and effective therapy dose optimization of a bispecific antibody 由 Wang, Yan, Pan, Donghui, Huang, Chenrong, Chen, Bingliang, Li, Mingzhu, Zhou, Shuaixiang, Wang, Lizhen, Wu, Min, Wang, Xinyu, Bian, Yicong, Yan, Junjie, Liu, Junjian, Yang, Min, Miao, Liyan

获取全文 获取全文 获取全文

PD-L1/LAG-3 bispecific antibody enhances tumor-specific immunity 由 Jiang, Haiping, Ni, Haiqing, Zhang, Pan, Guo, Xiaoli, Wu, Min, Shen, Haoran, Wang, Jie, Wu, Weiwei, Wu, Zhihai, Ding, Jiazheng, Tang, Rong, Zhou, Shuaixiang, Chen, Bingliang, Yu, Michael, Jing, Hua, Liu, Junjian

获取全文 获取全文 获取全文

Cancer immune therapy with PD-1-dependent CD137 co-stimulation provides localized tumour killing without systemic toxicity 由 Qiao, Yunqian, Qiu, Yangmin, Ding, Jie, Luo, Nana, Wang, Hao, Ling, Xiaomin, Sun, Jiya, Wu, Zhihai, Wang, Yisen, Liu, Yanpeng, Guo, Feifei, Sun, Ta, Shen, Wanwan, Zhang, Min, Wu, Dongdong, Chen, Bingliang, Xu, Wei, Wang, Xuan

获取全文 获取全文 获取全文

Optimal target saturation of ligand-blocking anti-GITR antibody IBI37G5 dictates FcγR-independent GITR agonism and antitumor activity 由 Liu, Huisi, Wu, Weiwei, Sun, Gangyu, Chia, Tiongsun, Cao, Lei, Liu, Xiaodan, Guan, Jian, Fu, Fenggen, Yao, Ying, Wu, Zhihai, Zhou, Shuaixiang, Wang, Jie, Lu, Jia, Kuang, Zhihui, Wu, Min, He, Luan, Shao, Zhiyuan, Wu, Dongdong, Chen, Bingliang, Xu, Wenqing, Wang, Zhizhi, He, Kaijie

获取全文 获取全文 获取全文